Article

Phosphodiesterase-5 Inhibition in Chronic Heart Failure - An Emerging Therapeutic Opportunity

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating

Acknowledgements:The author is grateful to the Monzino Foundation for supporting research activity on heart failure.

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Inhibitors of phosphodiesterase-5 (PDE5) are a class of drug that were originally developed as anti-ischaemic agents based on their ability to overexpress the nitric oxide (NO) pathway pursued via cyclic guanosine monophosphate (cGMP) signalling. Since the effects on myocardial oxygen consumption determinants were found to be less relevant than expected,1 they were not considered to have a real advantage over commonly used nitrates. However, later on the clinical applicability of the enhanced NO/cGMP pathway in terms of inhibiting PDE5 activity was felt to be more relevant than previously thought. Accordingly, over the last few years the use of PDE5 inhibitors has been expanded to the therapeutic management of some cardiovascular disorders, including heart failure (HF).

Phosphodiesterases

PDE5 comprises an enzyme superfamily with 11 subfamilies that hydrolyse the phosphodiester bond of cGMP and cyclic adenosine monophosphate (cAMP) to form the inactive 5’-GMP and 5’-AMP. PDEs have been characterised on the basis of amino acid sequence, substrate specificity, pharmacological properties and allosteric regulation. Within these families more than 40 isoforms are expressed either by different genes or as an expression of the same gene through alternative splicing.2 The substrate specificities include enzymes that are specific for cyclic AMP hydrolysis, enzymes for cyclic GMP hydrolysis3 and those that hydrolyse both. The importance of PDEs as regulators of signalling is evident from their development as drug targets in diseases such as asthma and obstructive pulmonary disease, cardiovascular diseases such as HF and atherosclerotic peripheral disease, neurological disorders and erectile dysfunction.

Among all PDEs, PDE5, which is inhibited by sildenafil and other inhibitors of clinical use, has been widely investigated.2 Three PDE5 isoforms have been described: PDE5 A1, A2 and A3.4 The PDE5 A1 and A2 isoforms are expressed in several tissues including the brain, lungs, heart, kidneys, bladder, prostate, urethra, penis, uterus and skeletal muscle. The A3 isoform is located in tissues having cardiac or smooth muscle constituents, such as the heart, bladder, prostate, urethra, penis, uterus and skeletal muscle.

Phosphodiesterase-5 Inhibitors

Sildenafil (Viagra), vardenafil (Levitra) and tadanafil (Cialis) are the three specific PDE5 inhibitors in current clinical use,5 which, despite similar although not identical mechanisms of action and structural similarity, present some significant differences regarding potency and selectivity. For instance, Vardenafil is 32-fold more potent than sildenafil in inhibiting PDE5:6 in the rat aorta, vardenafil but not sildenafil or tadalafil affects serum calcium (Ca++) handling to produce relaxation in addition to the typical increase of cGMP mediated by PDE5 inhibition.7

In experimental and clinical cardiology, sildenafil is the more extensively investigated agent. Sildenafil, although very selective for PDE5, shows some cross-reactivity with PDE6, which is predominant in photoreceptors8 and may transiently disturb colour vision perception in individuals taking high doses of sildenafil.9 Another cross-reactivity is that found with PDE11, which may be responsible for the development of back pain and myalgia as side effects of tadanafil due to the low selectivity of the compound for PDE5 over PDE11.

Sildenafil shows a rapid onset of activity, and plasma half-life is four hours.10–12 Empirical testing shows that the duration of action of sildenafil may reach 12 hours.13 The results of numerous studies consistently suggest that more commonly used drugs do not disturb the pharmacokinetics of sildenafil, and that the compound is well tolerated and does not interfere with the physiological effects of most drugs.

Use of Phosphodiesterase-5 Inhibition in Heart Failure

Vasoconstriction is a pathophysiological hallmark of HF, which involves the systemic and the pulmonary circulation. A defective NO pathway is central to HF syndromes. Among strategies to enhance in vivo NO-based mechanisms, inhibition of PDE514 has attracted interest as a potential therapeutic tool in HF prompted by experience accumulated in patients with pulmonary vascular hypertension.15

Pulmonary Circulation and Gas Diffusion

Given the high selectivity of PDE5 for the pulmonary microvessels, lung haemodynamics has reasonably been regarded as the primary target of PDE5 inhibitors in HF. The potential favourable therapeutic properties of PDE5 inhibition on pulmonary vascular remodelling and lung microvessel over-reactivity to vasoconstrictor stimuli has been the rationale for a number of studies.16–19

Similar to what has been described for idiopathic pulmonary hypertension, studies performed by Guazzi et al.16 and by Lewis et al.17 in patients with chronic HF and secondary pulmonary hypertension have shown that oral acute sildenafil 50mg lowers the pulmonary vascular pressure and resistance without significantly affecting the systemic arterial and wedge pulmonary pressures. The response of cardiac output is variable and in part related to the severity of the disease. The resistance-lowering effect of sildenafil in the pulmonary circulation at rest is also evident during exercise. Recently, the same authors have reported that the PDE5 inhibitor maintains the same efficacy during long-term prescription.18,19

An additional finding by Guazzi et al.16 is that sildenafil improves the lung diffusion capacity for carbon monoxide (DLCO) by more than 10% in patients with CHF through a selective increase of the DM component (alveolar capillary membrane conductance) of DLCO without affecting the pulmonary capillary volume of blood (Vc) available for gas exchange (the other component of DLCO). This is significant because not only does it prove the ability of PDE5 inhibition to influence one of the lung functional shortcomings in CHF, but also because it suggests that a defective NO/cGMP pathway is involved in the shortcoming.

Systemic Haemodynamics and Endothelial Function

Impaired vasomotion and endothelial dysfunction are hallmarks of HF that increase systemic vascular resistance (SVR). Hirata et al.20 investigated the acute effects of oral sildenafil 50mg on SVR, large artery stiffness and wave reflection as major determinants of left ventricular ejection impedance. They found a parallel decrease of these variables with an improvement in cardiac performance. A similar effect on aortic pressure augmentation index has been observed in patients with hypertensive heart disease.21

Due to these effects on large-conduit systemic arteries, sildenafil has been suggested to have an indication also in the management of systemic hypertension, especially of the isolated systolic form. Oliver et al.22 demonstrated that prolonged (three-month) administration of sildenafil 50mg three times a day to patients with high blood pressure induced a modulation of the arterial wave reflection and lowered systolic and diastolic ambulatory pressure by an average of 8 and 6mmHg, respectively.

A number of studies suggest that sildenafil may also improve endothelial dysfunction due to HF.23,24 In a report in which sildenafil was tested in patients with stable HF at doses of 12.5, 25 and 50mg, flow-mediated dilatation in the forearm circulation increased in a dose-dependent effect, and the lowest effective dose was shown to be 25mg. An additional endothelial effect of sildenafil 50mg on top of the angiotensin-converting enzyme (ACE) inhibitor ramipril was also demonstrated in patients with heart failure by Hryniewicz et al.25 Interestingly, according to observations obtained in a canine model of cardiac failure, sildenafil produced haemodynamic effects reminiscent of those produced by B-type natriuretic peptides26 and exerted a cumulative influence on pulmonary blood pressure elevation. Considering that resistance to the natriuretic peptide in HF is in part related to increased PDE5 activity, a combined approach and an additional therapeutic role for PDE5 inhibition may be prospectively investigated.

Cardiac Remodelling

PDE5 has been shown to prevent the development of cardiac hypertrophy, ischaemia-reperfusion injury and excessive adrenergic stimulation; PDE5 inhibition can prevent these protective activities. Sildenafil reverses hypertrophy27,28 through a cGMP-mediated effect in hypertrophic and failing hearts by sustained exposition to pressure overload. In a rat model of isoproterenol-induced cardiac hypertrophy, an inverse correlation was consistently evident between cGMP heart content and severity of hypertrophy.29 However, cGMP catabolism regulates cardiac adrenergic stimulation.30 Sildenafil also exhibits a direct protective property against myocite apoptosis,28 an effect also observed in a model of cardiac dysfunction secondary to doxorubicin cardiotoxicity.31

Benefits of sildenafil on experimental post-myocardial infarction (MI) ventricular remodelling have recently been reported by several authors.32,33 In particular, recent findings by Salloum et al. obtained in a murine model document that sildenafil modulates reactive post-MI hypertrophy and attenuates late adverse remodelling through myocite savage and reduced apoptotic cell death.33 There is also recent evidence that PDE5 is highly expressed in the hypertrophied human right ventricle and that acute PDE5 inhibition improves contractility.34

In the human heart, PDE5 is basically involved in the contractile response to β-adrenergic receptor stimulation35 and sildenafil blunts the inotropic response. Acute sildenafil also reduces the cardiac norepinephrine spillover, which seemingly results from an inhibition of the sympathetic outflow to the heart.36

Exercise Performance and Gas Exchange Analysis

Studies have consistently found that peak oxygen consumption (VO2) is improved by sildenafil in heart failure,16,17 and several mechanisms may be involved in this effect: the increased NO availability may promote the alveolar capillary membrane gas conductance improvement;16 the cGMP-mediated lowering effect of pulmonary arterial pressure and vascular resistance decreases the right ventricular afterload and improves right ventricular output and lung perfusion; and a better right ventricular function and a diminished peripheral resistance that improve left ventricular output and systemic perfusion.

Another relevant effect observed during exercise is a modulation of the excessive ventilation (VE) response to exercise in relation to carbon dioxide (CO2) output (VE/VCO2) commonly seen in patients with HF.37,38 Reasons for VE inefficiency may be a lung VE/perfusion mismatch or an overstimulation of the centres that control ventilation due to an excessive responsiveness of the reflexogenic areas of the cardiovascular system, or of the exercising muscle metaboreceptors.

The favourable effect of sildenafil on VE/VCO2 slope has been demonstrated both acutely and in the long term,16–19 possibly through a decrease of waste ventilation, as prospected by a reduction of the dead space to tidal volume ratio and by a facilitated alveolar–capillary membrane gas conductance.16,17,19 On the other hand, abnormal skeletal muscle signalling due to stimulation by muscle metabolic by-products (ergoreflex) is becoming a prominent concept in our quest to understand and treat HF. It is conceivable that muscle reflex contribution to VE can be reduced by improving endothelial function and upregulating muscle perfusion. Specifically, it has been proved that sildenafil intake can produce an endothelium-mediated attenuation of the peripheral stimulus to hyperventilation and breathlessness, and this effect results in an improved exercise ventilatory efficiency.19,39

Conclusions and Perspectives

An impaired NO pathway is typical of HF patients and contributes to several abnormalities in cardiac and vascular function. PDE5 inhibition is a new therapeutic strategy for overexpressing NO signalling by increasing cGMP availability and progressively accumulating evidence to support the use of this class of compounds across HF populations. However, initial promising perspectives await confirmation by large-scale randomised controlled trials.

References

  1. Jackson G, Gillies H, Osterloh I, Past, present and future: a seven-year update of Viagra (sildenafil citrate), Int J Clin Pract, 2005;59:680–91.
    Crossref | PubMed
  2. Francis SH, Turko IV, Corbin JD, Cyclic nucleotide phosphodiesterases: relating structure and function, Prog Nucleic Acid Res Mol Biol, 2001;65:1–52.
    Crossref | PubMed
  3. Mehats C, Andersen CB, Filopanti M, et al., Cyclic nucleotide phosphodiesterases and their role in endocrine cell signalling, Trends Endocrinol Metab, 2002;13:29–35.
    Crossref | PubMed
  4. Lin CS, Lau A, Tu R, Lue TF, Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum, Biochem Biophys Res Commun, 2000;268:628–35.
    Crossref | PubMed
  5. Boyle CD, Xu R, Asberom T, et al., Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED, Bioorg Med Chem Lett, 2005;15: 2365–9.
    Crossref | PubMed
  6. Zoraghi R, Corbin JD, Francis SH, Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity, J Biol Chem, 2006;281: 5553–8.
    Crossref | PubMed
  7. Teixeira CE, Priviero FB, Webb RC, Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta, J Pharmacol Exp Ther, 2006;316:654–61.
    Crossref | PubMed
  8. Ballard SA, Gingell CJ, Tang K, et al., Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes, J Urol, 1998;159:2164–71.
    Crossref | PubMed
  9. Goldstein I, Lue TF, Padma-Nathan H, et al., Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group, N Engl J Med, 1998;338:1397–1404.
    Crossref | PubMed
  10. Boolell M, Allen MJ, Ballard SA, et al., Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res, 1996;8:47–52.
    PubMed
  11. Padma-Nathan H, Stecher VJ, Sweeney M, et al., Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial, Urology, 2003;62:400–403.
    Crossref | PubMed
  12. Walker DK, Ackland MJ, James GC, et al., Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man, Xenobiotica, 1999;29:297–310.
    Crossref | PubMed
  13. Moncada I, Jara J, Subirá D, et al., Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window, Eur Urol, 2004;46:357–60.
    Crossref | PubMed
  14. Palmer RM, Ashton DS, Moncada S, Vascular endothelial cells synthesize nitric oxide from L-arginine, Nature, 1988;333:664–6.
    Crossref | PubMed
  15. Galiè N, Ghofrani HA, Torbicki A, et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension, N Engl J Med, 2005;353:2148–57.
    Crossref | PubMed
  16. Guazzi M, Tumminello G, Di Marco F, et al., The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure, J Am Coll Cardiol, 2004;44:2339–48.
    Crossref | PubMed
  17. Lewis GD, Lachmann J, Camuso J, et al., Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure, Circulation, 2007;115:59–66.
    Crossref | PubMed
  18. Lewis GD, Shah R, Shahzad K, et al., Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension, Circulation, 2007;116: 1555–62.
    Crossref | PubMed
  19. Guazzi M, Samaja M, Arena R, et al., Long-term use of sildenafil in the therapeutic management of heart failure, J Am Coll Cardiol, 2007;50:2136–44.
    Crossref | PubMed
  20. Hirata K, Adji A, Vlachopoulos C, O’Rourke MF, Effect of sildenafil on cardiac performance in patients with heart failure, Am J Cardiol, 2005;96:1436–40.
    Crossref | PubMed
  21. Mahmud A, Hennessy M, Feely J, Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men, J Hum Hypertens, 2001;15:707–13.
    Crossref | PubMed
  22. Oliver JJ, Melville VP, Webb DJ, Effect of regular phosphodiesterase type 5 inhibition in hypertension, Hypertension, 2006;48:622–7.
    Crossref | PubMed
  23. Katz SD, Balidemaj K, Homma S, et al., Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure, J Am Coll Cardiol, 2000;36:845–51.
    Crossref | PubMed
  24. Guazzi M, Tumminello G, Di Marco F, Guazzi MD, Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure, Clin Pharmacol Ther, 2004;76:371–8.
    Crossref | PubMed
  25. Hryniewicz K, Dimayuga C, Hudaihed A, et al., Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure, Clin Sci, 2005;108:331–8.
    Crossref | PubMed
  26. Forfia PR, Lee M, Tunin RS, et al., Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart, J Am Coll Cardiol, 2007;49:1079–88.
    Crossref | PubMed
  27. Takimoto E, Champion HC, Li M, et al., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy, Nat Med, 2005;11:214–22.
    Crossref | PubMed
  28. Das A, Xi L, Kukreja RC, Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling, J Biol Chem, 2005;280:12944–55.
    Crossref | PubMed
  29. Hassan MA, Ketat AF, Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T, BMC Pharmacol, 2005;5:10.
    Crossref | PubMed
  30. Takimoto E, Champion HC, Belardi D, et al., cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism, Circ Res, 2005;96: 100–109.
    Crossref | PubMed
  31. Fisher PW, Salloum F, Das A, et al., Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity, Circulation, 2005;111:1601–10.
    Crossref | PubMed
  32. Pérez NG, Piaggio MR, Ennis IL, et al., Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction, Hypertension, 2007;49: 1095–1103.
    Crossref | PubMed
  33. Salloum FN, Abbate A, Das A, et al., Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice, Am J Physiol Heart Circ Physiol, 2008;294:1398–1406
    Crossref | PubMed
  34. Nagendran J, Archer SL, Soliman D, et al., Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility, Circulation, 2007;116:238–48.
    Crossref | PubMed
  35. Borlaug BA, Melenovsky V, Marhin T, et al., Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans, Circulation, 2005;112:2642–9.
    Crossref | PubMed
  36. Al-Hesayen A, Floras JS, Parker JD, The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure, Eur J Heart Fail, 2006;8:864–8.
    Crossref | PubMed
  37. Guazzi M, Reina G, Tumminello G, Guazzi MD, Exercise ventilation inefficiency and cardiovascular mortality in heart failure, Eur Heart J, 2005;26:472–80.
    Crossref | PubMed
  38. Arena R, Myers J, Abella J, et al., Development of a ventilatory classification system in patients with heart failure, Circulation, 2007;115:2410–17.
    Crossref | PubMed
  39. Guazzi M, Casali M, Berti F, et al., Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients, Clin Pharmacol Ther, 2008;83:336–41.
    Crossref | PubMed